2021.08.24
Closing of the Series C funding to advance pipeline of novel GPCR antibodies
NBHL has closed the Series C funding to advance pipeline of novel GPCR antibodies.
Click here for detail.
Announcement of Agreements with ReCentrics Biotechnology Co. Ltd. and NBHL for Global Collaboration to Development and Commercialize GPCR Antibody Therapies
NBHL has singed the Agreements with ReCentrics Biotechnology Co. Ltd. and NBHL for Global Collaboration to Development and Commercialize GPCR Antibody Therapies.
Click here for details.
